markets: How will Biosecure Act impact Indian pharma companies? Aditya Khemka explains

markets: How will Biosecure Act impact Indian pharma companies? Aditya Khemka explains

“There should be an alternate vendor that can support you, even if at higher prices or higher cost. So, I think that is where the Indian players come in. Remember, last we checked, Indian API exports were around $4 billion and that number compares to China’s API exports of roughly $40 billion,” says Aditya Khemka, … Read more

stock picks: 2 sectors Aditya Arora is bullish on for near term

stock picks: 2 sectors Aditya Arora is bullish on for near term

“One day we see a gap up and another day we see a gap down. So, market is directionless and choppy. So, in such kind of a market, fmcg space and pharma space is doing pretty well, so I like that space,” says Aditya Arora, Adlytick.This has been a very difficult last one, one-and-a-half month. … Read more

Street Favourites! 7 smallcap stocks with high analyst ratings that can deliver up to 40% returns – Solid Outlook

Street Favourites! 7 smallcap stocks with high analyst ratings that can deliver up to 40% returns – Solid Outlook

Indian Railway Finance Corporation Share Price 199.68 10:12 AM | 10 Jul 2024 3.84(1.96%) One97 Communications Share Price 463.4 10:11 AM | 10 Jul 2024 1.75(0.38%) YES Bank Share Price 25.19 10:11 AM | 10 Jul 2024 -0.61(-2.37%) ITC Share Price 451.5 10:11 AM | 10 Jul 2024 -1.11(-0.25%) HDFC Bank Share Price 1635.75 10:12 … Read more

Turnaround stocks: 10 companies that returned to profit in Q4 – Red to Black

Turnaround stocks: 10 companies that returned to profit in Q4 – Red to Black

Jun 15, 2024, 10:24:53 AM IST In the March quarter of FY24, several companies transitioned from loss-making to profit-making. According to Ace Equity data, Piramal Pharma, Inox Wind Energy, BHEL, Sunteck Realty, Tejas Networks, and others turned profitable in Q4FY24. Here is the list: Shutterstock.com ​Piramal Pharma clocked a profit of Rs 89.23 crore in … Read more

Piramal Pharma: In 3-5 years, Piramal Pharma can see 22- 25% EBITDA growth margins: Nandini Piramal

Piramal Pharma: In 3-5 years, Piramal Pharma can see 22- 25% EBITDA growth margins: Nandini Piramal

Nandini Piramal, Chairperson, Piramal Pharma, says “for FY25, we are actually guiding an early teens absolute improvement in revenue and early teens margin growth as well. So, that is what I can say for FY26. In three to five years, we can see 22- 25% EBITDA growth margins.”This time your margins were close to like … Read more

Big movers on D-Street: What should investors do with Varun Beverages, BEML and Piramal Pharma?

Big movers on D-Street: What should investors do with Varun Beverages, BEML and Piramal Pharma?

Domestic indices staged a dramatic rebound on Monday to settle higher, helped by buying at the fag-end. The 30-share BSE Sensex rose 111 points at 72,776 and the Nifty rose 48 points to 22,104.05. Stocks that were in focus include names like Varun Beverages, which rose 0.73%, BEML, which increased 14.5%, and Piramal Pharma, whose … Read more

Hot Stocks: Brokerage view on Infosys, HDFC Bank, Piramal Pharma and Indigo

Hot Stocks: Brokerage view on Infosys, HDFC Bank, Piramal Pharma and Indigo

Brokerage Nomura maintained a neutral rating on HDFC Bank, Kotak Mahindra Bank has a buy rating on InterGlobe Aviation, Jefferies recommended a buy on Piramal Pharma and UBS maintained a buy on Infosys. We have collated a list of recommendations from top brokerage firms from ETNow and other sources: Nomura on HDFC Bank: Neutral| Target … Read more